Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was performed on 26 DL patients. Seventeen patients underwent resection and 9 had a biopsy. 23 patients could be assessed for a response to treatment after surgery. 13 received focal radiotherapy (RT), 6 whole brain RT (WBRT), 3 chemotherapy alone and 1 chemotherapy followed by WBRT. 22 achieved complete response (CR) and one a partial response (PR). Four patients relapsed (2 local and 2 systemic). Median follow up was 64 months, with median PFS and OS not reached. Three year PFS was 89% (95% CI 0.64–0.97). All patients are alive at last follow-up, demonstrating that DL is an indolent tumor with long survival. CR is achievable with focal therapy in the majority of cases, but there is a risk for relapses and long-term follow-up is recommended.